Antibody Therapeutics Xchange - Boston - 2025

Bi/Multispecifics
- Bi/Multispecifics
11:20 12:20

Technologies accelerating engineering into advanced modalities
Formats & Scaffolds
- Formats & Scaffolds
11:20 12:20

Challenges of using single domain antibodies as new modalities of multifunctional biologics
Lead Identification & Optimization
- Lead Identification & Optimization
11:20 12:20

Stop shooting in the dark: Leveraging early structural insights to power rational antibody lead design & optimization
Target Selection & Mechanisms of Action
- Target Selection & Mechanisms of Action
09:05 10:05

Overcoming membrane protein complexes using display technologies

Valeria Busygina, Director, Biologics Design and Display - Merck
Target Selection & Mechanisms of Action
- Target Selection & Mechanisms of Action
15:15 15:45

Sponsor-led Poster Presentation: Lead Identification & Optimization topic: Integration of Rabbit Antibody Discovery with LENSai as a Comprehensive Solution for Therapeutics Generation
Formats & Scaffolds
- Formats & Scaffolds
15:15 15:45

Sponsor-led Poster Presentation: Current challenges in design of bispecific/ chimeric antigen receptors for solid tumours
Bi/Multispecifics
- Bi/Multispecifics
15:15 15:45

Poster Presentation: Solving the Bispecific Antibody Mispairing Challenge in Preclinical R&D

Efficient bispecific antibody (bsAb) production requires precise assembly of multiple chains. Combin ...

Richard Park, Sr. Dir, Business Development - Evitria
Lead Identification & Optimization
- Lead Identification & Optimization
15:15 15:45

Sponsor-led Poster Presentation: De Novo Protein Sequencing for Identification of Neutralizing Antibodies in Human Plasma
Formats & Scaffolds
- Formats & Scaffolds
09:05 10:05

Addressing engineering challenges with bispecific and immunocytokine drugs

How to solve the challenges of small therapeutic windows for cytokine treatment Manufacturing and st ...

Randall Burton, Director Biologics - Quotient Therapeutics
Bi/Multispecifics
- Bi/Multispecifics
15:50 16:50

Bi/Multispecific antibodies: challenges in translation

How do translational efficacy and safety assessments contribute to the selection of optimal molecule ...

Bart Hendriks, Executive Director PK Sciences - Oncology - Novartis
Lead Identification & Optimization
- Lead Identification & Optimization
09:05 10:05

Harnessing emerging technologies and platforms for rapid lead identification and deeper optimization across various modalities

Are current antibody discovery platforms and screening strategies meeting our expectations for effec ...

Sarav Narayanan, Associate Scientific Director - Takeda
Target Selection & Mechanisms of Action
- Target Selection & Mechanisms of Action
11:20 12:20

Target selection to avoid off-target effect and cross-reactivity with healthy tissues
- Bi/Multispecifics
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection & Mechanisms of Action
13:25 13:55

Spotlight Presentation:
- Bi/Multispecifics
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection & Mechanisms of Action
16:50 17:50

Drinks-Canape Reception
- Bi/Multispecifics
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection & Mechanisms of Action
15:05 15:15

Afternoon Refreshments
- Bi/Multispecifics
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection & Mechanisms of Action
14:00 14:30

1-2-1 Meetings / Networking Break
- Bi/Multispecifics
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection & Mechanisms of Action
14:35 15:05

1-2-1 Meetings / Networking Break
- Bi/Multispecifics
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection & Mechanisms of Action
12:20 13:20

Networking Lunch
- Bi/Multispecifics
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection & Mechanisms of Action
11:10 11:20

Morning Refreshments
- Bi/Multispecifics
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection & Mechanisms of Action
10:40 11:10

1-2-1 Meetings / Networking Break
- Bi/Multispecifics
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection & Mechanisms of Action
10:10 10:40

1-2-1 Meetings / Networking Break
Bi/Multispecifics
- Bi/Multispecifics
09:05 10:05

Developability / manufacturability of bispecifics

Zhinan Xia, Founder & CSO - Abimmune Bio
Lead Identification & Optimization
- Lead Identification & Optimization
15:50 16:50

Leveraging AI and early structural insights to power rational antibody lead design and optimization

Where does AI stand on de novo antibody design? How can human BCR and single cell sequencing data i ...

Xingfeng Bao, VP of Biology - GV20 Therapeutics
Target Selection and Mechanisms of Action
- Target Selection & Mechanisms of Action
15:50 16:50

Enhancing antigen-specific binding affinity for improved clinical efficacy

What are some challenges in affinity maturation of antibodies against membrane proteins and how have ...

Hayretin Yumerefendi, Associate Director - Novartis
- Bi/Multispecifics
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection & Mechanisms of Action
08:30 09:00

Opening Address & Keynote Presentation:
- Bi/Multispecifics
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection & Mechanisms of Action
08:00 08:30

Registration